Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163).

Timothy J. Kennedy,Mihir M. Shah,Haejin In,Jennifer W. Chuy,Dirk F. Moore,David A. Kooby,Rafi Kabarriti,Stephen Szabo,Howard S. Hochster,Salma K. Jabbour

Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163).

2021

Timothy J. Kennedy
Mihir M. Shah
Haejin In
Jennifer W. Chuy
Dirk F. Moore
David A. Kooby
Rafi Kabarriti
Stephen Szabo
Howard S. Hochster
Salma K. Jabbour

e16111Background: Despite advances in therapy, outcomes of patients with gastric cancer in the US remain poor. Recent data demonstrated that certain subtypes of gastric cancer are less responsive t...

Keywords:

Internal medicine
Medicine
locally advanced
Interim
PD-L1 Positive
Oncology
Pembrolizumab
Cancer
EBV Positive
Adjuvant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations